In contrast, a study conducted in Korea found significantly inferior 10‐year DFS and more contralateral breast cancer in BRCA1/2 carriers than non‐carriers, but no significant difference in 10‐year OS.44 This evidence concerns the gene BRCA1 and breast cancer.